Bio-Rad Laboratories, Inc. $BIO Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lowered its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 2.9% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,793,537 shares of the medical research company’s stock after selling 53,006 shares during the quarter. Vanguard Group Inc. owned 6.63% of Bio-Rad Laboratories worth $502,890,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in BIO. Royal Bank of Canada increased its stake in shares of Bio-Rad Laboratories by 25.2% during the first quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company’s stock worth $7,382,000 after purchasing an additional 6,100 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Bio-Rad Laboratories by 45.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company’s stock worth $25,575,000 after buying an additional 32,874 shares in the last quarter. Empowered Funds LLC increased its stake in Bio-Rad Laboratories by 14.8% during the 1st quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company’s stock worth $377,000 after buying an additional 199 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Bio-Rad Laboratories by 95.3% during the first quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company’s stock valued at $9,105,000 after acquiring an additional 18,239 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D lifted its position in shares of Bio-Rad Laboratories by 20.1% in the second quarter. State of New Jersey Common Pension Fund D now owns 8,292 shares of the medical research company’s stock valued at $2,001,000 after acquiring an additional 1,387 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BIO has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 29th. Wells Fargo & Company upped their target price on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Citigroup increased their price objective on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $358.50.

Bio-Rad Laboratories Stock Up 0.4%

BIO stock opened at $269.71 on Thursday. Bio-Rad Laboratories, Inc. has a one year low of $211.43 and a one year high of $343.12. The firm has a market cap of $7.28 billion, a PE ratio of 9.66 and a beta of 1.18. The firm’s 50 day moving average price is $299.08 and its 200-day moving average price is $301.34. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.19 and a current ratio of 5.62.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, February 12th. The medical research company reported $2.51 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.57 by ($0.06). The business had revenue of $693.20 million for the quarter, compared to analyst estimates of $694.64 million. Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.Bio-Rad Laboratories’s revenue was up 3.9% compared to the same quarter last year. During the same period last year, the business earned $2.90 EPS. On average, equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.